Participation in two phase II prophylactic HIV vaccine trials in the UK

被引:10
作者
Gray, Kimberly [1 ,2 ]
Legg, K. [3 ]
Sharp, A. [2 ]
Mackie, N. [3 ]
Olarinde, F. [2 ]
De Souza, C. [3 ]
Weber, J. [3 ]
Peters, B. [2 ]
机构
[1] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5T 3M7, Canada
[2] Kings Coll London, Guys & St Thomas Hosp, London, England
[3] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, London SW7 2AZ, England
关键词
HIV prophylactic vaccines; recruitment; guidelines;
D O I
10.1016/j.vaccine.2008.03.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There will be a continued imperative to recruit large numbers of healthy volunteers to early phase prophylactic HIV vaccine (PHV) trials. We studied mechanisms associated with participation in two related phase II PHV trials. The most cited reasons for volunteering were altruism and a personal connection to HIV. The most successful recruiting strategies targeted organisations dealing with HIV, health or social issues, or were directed to large audiences through the mass media. However, circulated emails and word of mouth were the most resource-effective approaches. Group discussions and the collection of a pool of potential volunteers were much less effective than one-to-one discussions and immediate screening after recruitment. We utilised our findings to devise key recommendations to assist PHV trial teams who are planning future studies. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2919 / 2924
页数:6
相关论文
共 28 条
[1]   Trial-related discrimination in HIV vaccine clinical trials [J].
Allen, M ;
Israel, H ;
Rybczyk, K ;
Pugliese, MA ;
Loughran, K ;
Wagner, L ;
Erb, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (08) :667-674
[2]  
[Anonymous], AIDS EP UPD SPEC REP
[3]   The global HIV/AIDS vaccine enterprise: Scientific strategic plan [J].
Bhan, MK ;
Berkley, S ;
DeWilde, M ;
Esparza, J ;
Fauci, AS ;
Gayle, H ;
Johnston, MI ;
Kaleebu, P ;
Kazatch-Kine, MD ;
Klausner, RD ;
Lander, ES ;
Makgoba, MW ;
Mocumbi, P ;
Piot, P ;
Quintana-Trias, O ;
Snow, W ;
Walport, MJ ;
Wigzell, H .
PLOS MEDICINE, 2005, 2 (02) :111-121
[4]   HIV vaccine trial preparedness among Spanish-speaking Latinos in the US [J].
Brooks, R. A. ;
Newman, P. A. ;
Duan, N. ;
Ortiz, D. J. .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2007, 19 (01) :52-58
[5]   Determinants of enrollment in a preventive HIV vaccine trial [J].
Buchbinder, SP ;
Metch, B ;
Holte, SE ;
Scheer, S ;
Coletti, A ;
Vittinghoff, E .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (01) :604-612
[6]  
CHESNEY MA, 1995, J ACQ IMMUN DEF SYND, V9, P30
[7]   Aids research - Promising AIDS vaccine's failure leaves field reeling [J].
Cohen, Jon .
SCIENCE, 2007, 318 (5847) :28-29
[8]   Motivations for participating in an HIV vaccine efficacy trial [J].
Colfax, G ;
Buchbinder, S ;
Vamshidar, G ;
Celum, C ;
McKirnan, D ;
Neidig, J ;
Koblin, B ;
Gurwith, M ;
Bartholow, B .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (03) :359-364
[9]  
Crumbo C L, 1997, J Assoc Nurses AIDS Care, V8, P59, DOI 10.1016/S1055-3290(97)80029-5
[10]   Participant retention in clinical trials of candidate HIV vaccines [J].
de Bruyn, G ;
Hudgens, MG ;
Sullivan, PS ;
Duerr, AC .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (04) :499-501